These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2452316)

  • 1. Verapamil pharmacodynamics and disposition in obese hypertensive patients.
    Abernethy DR; Schwartz JB
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):209-15. PubMed ID: 2452316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats.
    Todd EL; Abernethy DR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):642-7. PubMed ID: 3735134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aging alters verapamil elimination and dynamics: single dose and steady-state responses.
    Schwartz JB
    J Pharmacol Exp Ther; 1990 Oct; 255(1):364-73. PubMed ID: 2213568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration.
    Abernethy DR; Wainer IW; Longstreth JA; Andrawis NS
    J Pharmacol Exp Ther; 1993 Aug; 266(2):904-11. PubMed ID: 8355215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil.
    Schwartz JB; Troconiz IF; Verotta D; Liu S; Capili H
    J Pharmacol Exp Ther; 1993 May; 265(2):690-8. PubMed ID: 8496816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions.
    Schwartz JB; Verotta D; Sheiner LB
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1032-8. PubMed ID: 2600802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
    Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
    J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of sufentanil in obese patients.
    Schwartz AE; Matteo RS; Ornstein E; Young WL; Myers KJ
    Anesth Analg; 1991 Dec; 73(6):790-3. PubMed ID: 1835321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
    Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
    Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Does hypertension have fewer complications in pregnancy in obese patients?].
    Chatellier G; Tchobroutsky C; Plouin PF
    Arch Mal Coeur Vaiss; 1987 Jun; 80(6):947-51. PubMed ID: 3116995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentration/effect relationship and enantioselective analysis of verapamil in hypertensive patients.
    Harder S; Thürmann P; Siewert M; Blume H; Rietbrock N; vander Kleijn J; Gierend M
    J Cardiovasc Pharmacol; 1992 May; 19(5):665-9. PubMed ID: 1381762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action.
    Mikus G; Eichelbaum M; Fischer C; Gumulka S; Klotz U; Kroemer HK
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1042-8. PubMed ID: 2359015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacology of verapamil. I. Elimination kinetics in dogs and correlation of plasma levels with effect on the eletrocardiogram.
    McAllister RG; Bourne DW; Dittert LW
    J Pharmacol Exp Ther; 1977 Jul; 202(1):38-44. PubMed ID: 874818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.
    Albrecht S; Ihmsen H; Hering W; Geisslinger G; Dingemanse J; Schwilden H; Schüttler J
    Clin Pharmacol Ther; 1999 Jun; 65(6):630-9. PubMed ID: 10391668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamic dose-response effects of i.v. verapamil in coronary artery disease.
    Silke B; Verma SP; Ahuja RC; Nelson GI; Hussain M; Taylor SH
    Herz; 1984 Dec; 9(6):353-61. PubMed ID: 6510876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of age, gender, and obesity on midazolam kinetics.
    Greenblatt DJ; Abernethy DR; Locniskar A; Harmatz JS; Limjuco RA; Shader RI
    Anesthesiology; 1984 Jul; 61(1):27-35. PubMed ID: 6742481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cimetidine disposition in obesity.
    Abernethy DR; Greenblatt DJ; Matlis R; Gugler R
    Am J Gastroenterol; 1984 Feb; 79(2):91-4. PubMed ID: 6364798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen.
    Abernethy DR; Greenblatt DJ; Divoll M; Shader RI
    J Lab Clin Med; 1983 Jun; 101(6):873-80. PubMed ID: 6133901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.
    Cheymol G; Weissenburger J; Poirier JM; Gellee C
    Br J Clin Pharmacol; 1995 Jun; 39(6):684-7. PubMed ID: 7654489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions.
    Lenz ML; Pool JL; Laddu AR; Varghese A; Johnston W; Taylor AA
    Am J Hypertens; 1995 Feb; 8(2):133-45. PubMed ID: 7755941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.